# Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

> **NCT07001618** · PHASE2 · RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 162 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** MaaT033 capsule
- **DRUG:** Cemiplimab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatine
- **DRUG:** Pemetrexed (Alimta)
- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** gemcitabine
- **DRUG:** Docetaxel
- **DRUG:** Vinorelbine i.v. 25 mg/m²
- **DRUG:** Vinorelbine oral

## Key facts

- **NCT ID:** NCT07001618
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-17
- **Primary completion:** 2030-09
- **Final completion:** 2032-09
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07001618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07001618, "Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07001618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*